Clinical trials: Glucagon
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Type 2, Diabetes Melletus
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
- Trial name
- ACHIEVE-RAM (NCT07613307)
- Testing
- Orforglipron
- Where
- 40 sites in India, Saudi Arabia and 2 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Systolic Hypertension
Blood Pressure Outcomes With Liraglutide Therapy
Purpose: The purpose of this study is to further study the mechanism by which liraglutide, a relatively new anti-hyperglycemic medication, might lower blood pressure in patients with Type 2 diabetes and high blood pressure.
- Trial name
- BOLT (NCT01755572)
- Testing
- Liraglutide
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Mount Sinai Hospital, Canada
Diabetes Mellitus, Type 2, Insulin Resistance
Characterization of the Incretinpathy in Type 2 Diabetes Initiated After Sixty Years Old
Type 2 diabetes (T2DM) is characterized by hyperglycemia, insulin resistance, absolute or relative insulin deficiency, hyperglucagonemia, increased hepatic glucose production, frequently accelerated gastric emptying and obesity.
- Trial name
- NCT00843232
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil
Healthy
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.
- Trial name
- GLP-2ant (NCT06774807)
- Testing
- Saline infusion, Saline injection, 1nmol antagonist infusion
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Short Bowel Syndrome
Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome
We plan to examine the gastrointestinal (GI) physiologic profile of Exenatide, a glucagon-like peptide (GLP-1) analog as a possible intestino-trophic growth factor capable of inducing small bowel adaptation and regeneration in…
- Trial name
- NCT01818648
- Testing
- Exenatide
- Sponsor
- Mayo Clinic
Diabetes Mellitus, Type 2, Obesity
Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Obesity and Insulin Resistance
Being overweight or obese has been associated with insulin resistance contributing to an increased risk for the development of type II diabetes.
- Trial name
- NCT04926415
- Testing
- taVNS
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Burrell College of Health Sciences
Hypoglycemia
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
- Trial name
- NCT01972152
- Testing
- G-Pen(TM) 1 mg, Lilly Glucagon(TM) 1 mg, G-Pen(TM) 0.5 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xeris Pharmaceuticals
Type 1 Diabetes, Hypoglycemia
Micro Glucagon During Exercise in Type 1 Diabetes
This proof-of-principle study to assess effects of different doses (mini and micro) of subcutaneous glucagon analog Dasiglucagon (Zealand Pharma, Copenhagen, Denmark) on the change in blood glucose concentration during…
- Trial name
- NCT04192019
- Testing
- Micro-glucagon, Mini-glucagon
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities.
- Trial name
- NCT07169136
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Type 1 Diabetes
The Role of Amylin and Glucagon in T1DM
The purpose of this study is to see if giving pramlintide and insulin before a meal would lower high blood sugar and if a glucagon (a naturally made hormone in the body but reduced in diabetes and its role is in prevention of low…
- Trial name
- NCT00206258
- Testing
- Pramlintide and glucagon
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Type 1 Diabetes
Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1
The investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection. The investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.
- Trial name
- NCT05960565
- Testing
- Glucagon
- Where
- Norway
- Volunteers
- 9 people
- Sponsor
- St. Olavs Hospital
Glucagon-Like Peptide-1 Receptor Agonists
HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects
To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.
- Trial name
- NCT06520540
- Testing
- HDM1002 100 mg QD 12weeks, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks，Q 2W for titration
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy Volunteers (HV)
A Study of IBI3042 in Healthy Adult Participants
This is a randomized, investigator- and participant-blinded, placebo-controlled, parallel-group, dose-escalation Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of IBI3042…
- Trial name
- NCT07842393
- Testing
- Investigational Drug: IBI3042
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fortvita Biologics (USA)Inc.
Diabetes Mellitus, Type 1
Feasibility Trial Testing the Bionic Pancreas With ZP4207
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus.
- Trial name
- dasiglucagon (NCT02971228)
- Testing
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Zealand Pharma
Pre-diabetes, Type 2 Diabetes
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
This study evaluates exenatide, sitagliptin, and glimepiride for the treatment of high blood sugar in patients with impaired fasting glucose or early type 2 diabetes.
- Trial name
- NCT00775684
- Testing
- Exenatide, Sitagliptin, Glimepiride
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Pennsylvania
Diabetes Type I
Sitagliptin in Type I Diabetic Patients
The purpose of the study is to evaluate the effect of sitagliptin on overall blood glucose concentrations in Type I Diabetic subjects.
- Trial name
- NCT01741103
- Testing
- sitagliptin
- Where
- United States
- Sponsor
- University at Buffalo
Multiple Sclerosis
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis.
- Trial name
- TAG-MS (NCT07497399)
- Testing
- NLY01
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Johns Hopkins University
Type 1 Diabetes
Dual-hormone Artificial Pancreas Versus Single-hormone Under Exercise and a Meal Challenge
The present clinical trial aims to examine alternative strategies for preventing/mitigating hypoglycemic events among adults with type 1 diabetes utilizing a highly personalized control system.
- Trial name
- TAILOR/3 (NCT06082973)
- Testing
- Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control, Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Universitat Politècnica de València
Obesity, Status Post Sleeve Gastrectomy
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
Background: Metabolic Bariatric Surgery, including a surgery called vertical sleeve gastrectomy, is the most effective weight loss treatment for severe obesity.
- Trial name
- NCT04883346
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)